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Introduction. Radiation therapy is an integral part in the combined treatment of breast cancer. The beneﬁt is well established in
terms of both local control and survival endpoints. Helical Tomotherapy has been proposed as an alternative to standard 3D
conformal radiotherapy.
Purpose. To evaluate dosimetric characteristics of Helical Tomotherapy for breast cancer radiotherapy.
Methods and materials. Nine patients with histologically proven breast cancer affecting internal mammary chain (clinically and/or
histologically conﬁrmed) stage IIIC, were included in this study. CT simulation scans were used to contourn the planning target
volumes (PTV) including the chest wall/breast, supraclavicular, axillary, and internal mammary lymph nodes. Dose prescription
was 50/50.4, in 25/28 fractions of 2/1.8Gy, to the PTV and treatment planning objectives were to cover at least 95% of the planning
target volume with the 95% isodose. Beamlet entrance and/or exit throughout critical structures was blocked to protect the lungs,
heart, and contralateral breast.
Results. Median homogeneity index (maximum dose/prescribed dose) was 1.23 (range 1.05–1.48). Median coverage index (min-
imum dose/prescribed dose) was 0.72 (range 0.54–0.9) Median V30, V20 and V5 for ipsilateral lung was 16.72% (range 0–26.5%),
30.8% (range 10.62–40%) and 97.6% (range 64.46–100%) respectively. Median V30, V20 and V5 for contralateral lung was 0% (range
0–0.48%), 0.095% (range 0–2.58%) and 49% (range 5.84–92.38%) respectively. Median V30, V20 and V5 for heart was 1.112% (range
0–4.6%), 4% (range 0.025–15.44%) and 96.52% (range 27.3–100%) respectively. Median V20, V10 and V5 for contralateral breast was
0% (range 0–0.37%), 1.25% (range 0.1–11.82%) and 28% (range 15.53–49.4%) respectively.
Conclusion. HT offers acceptable dose distribution. This technique achieves high homogeneity and conformality, and reduces the
hot-spots in organs at risk although increasing the low dose areas. However, clinical advantage of using HT in breast cancer is
unknown. Further studies of long monitoring period are required.
http://dx.doi.org/10.1016/j.rpor.2013.03.092
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Introduction. Breast cancer sensitivity to large fraction size may be enhanced using hypofractionated radiotherapy, thereby short-
ening overall treatment time. Purpose: To report early outcomes of whole-breast hypofractionation radiation scheme.
Methods and materials. Retrospective institutional review. Eligibility included breast cancer patients treated with hypofractionated
radiation therapy after conservative surgery. Node metastases or adjuvant chemotherapy were not exclusion criteria for this
analysis. The whole breast volume received 40.05Gy in 2.47Gy fractions with a sequential lumpectomy boost to administrate
10–20Gy in 5–10 fractions.
Results. Between January 2009 and June 2012, 182 patients were treated in our department; median age 65 years. Stage distribution
was as follows: TisN0, n=31; T1N0-1, n=103; T2N0-2, n=45; T3N1, n=2 and T4N0 n=1. With a median follow-up of 31 months
(range, 7–50 months) the median survival was 32 months (95% conﬁdence interval [CI] 29.2–34.8). Acute National Cancer Insti-
tute/Common Toxicity Criteria grade 1, 2 and 3 skin toxicity was observed in 47.2%, 12.1% and 2.1% respectively, and grade 1 lung
toxicity only in 1.6%. We observed 1 local relapse and 3 deaths, but only 2 were related to the tumor. Among the patients with ≥2-
year follow-up no toxicity higher than grade 2 was observed (Late Effects in Normal Tissues–Subjective, Objective, Management,
and Analytic scale).
Conclusions. The hypofractionated radiation schedule employed to whole-breast followed by sequential boost can be safety
administered. With current follow-up, the results are encouraging and suggest minimal side effects and excellent local control.
http://dx.doi.org/10.1016/j.rpor.2013.03.093
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Introduction. In the last years numerous studies have shown the equivalence between standard and hypofractionated treatment
in breast cancer in terms of local control.
Objective. Analyze, in terms of toxicity, the results of our institution in the treatment of patients in a hypofractionated way.
Materials and methods. We have analyzed all the patients treated in our service (from May 2009 to September 2012) following
the scheme of the study START B (40.05Gy/15 fractions). We excluded locally advanced cancers that had required mastectomy
